MedTrace Logo

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

NCT07525219 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-23

No results posted yet for this study

Summary

Local anesthetic infiltration is a primary source of acute pain during stereotactic procedures.

Conditions

  • Analgesic Efficacy

Interventions

DRUG

Suzetrigine

100mg - Medication is self-administered at home on an empty stomach approximately 1-6 hours prior to the procedure.

DRUG

acetaminophen

1000mg - Medication is self-administered at home on an empty stomach approximately 1-6 hours prior to the procedure.

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Stephen B Tatter, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07525219 on ClinicalTrials.gov